论文部分内容阅读
Patients may complain of pain at the injection site after subcutaneous (s.c.) administration of erythropoietin (EPO).Local pain due to s.c.EPO into the thigh was evaluated in 60 hemodialysis patients in a double-blind, placebo-controlled study.Identical volumes and concentrations (2000 IU in 0.5 ml) of phosphate-buffered epoetin-alpha (EPO-αph), citrate-buffered epoetin-alpha (EPO-αci) and epoetin-beta (EPO-β) were compared to 0.5 ml of 0.9% saline (SAL), used as placebo.The patients received the 4 injections at thesame occasion.For pain evaluation, a verbal scale ranging from no pain (0) to extremely painful (5) and a 10 cm ungraduated visual analogue score (VAS) (0 =no pain, 10 =maximal pain) were used.Treatment acceptance was assessed (yes/no) and expressed as apercentage of the population.Ranking of the preparations from 1 to.4 according to increasing local discomfort was performed.Median verbal pain scores and interquanile ranges were 1.0(0-2) for SAL,.0.0 (0-2) for EPO-β, 1.5 (0-3) for EPO-αph (p ≤0.05 vs SAL and EPO-β)and 3.0 (2-4) for EPO-αci (p ≤0.001 vs EPO-αph).VAS was 0.9 (0.5-2.5) for SAL, 0.9 (0.4-2.4) for EPO-β, 2.7 (0.8-5.7) for EPO-αph (p ≤0.001 vs SAL and EPO-β) and 4.2 (1.7-6.4) for EPO-αci (p ≤0.001 vs EPO-αph).Treatment acceptance was 73% for SAL, 78% for EPO-β, 60% for EPOαph (p ≤0.05 vs EPO-β) and 32% for EPO-αci (p ≤0.05 vs EPO-αph).Ranking was.2 (1-3)for SAL, 2 (1-2) for EPO-β, 3 (1-4) for EPO-αph (p ≤0.05 vs SAL and EPO-β) and 4 (3-4) for EPO-αci (p ≤0.05 vs SAL and EPO-β) and 4 (3-4) for EPO-αci (p ≤0.001 vs EPO-αph).In conclusion, s.c.EPO-αph is better accepted than s.c.EPO-αci.However, s.c.EPO-β is less painful.